Cargando…

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy

Detalles Bibliográficos
Autores principales:	Ullrich, Evelyn, Vogler, Meike, von Metzler, Ivana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388638/ https://www.ncbi.nlm.nih.gov/pubmed/35982042 http://dx.doi.org/10.1038/s41392-022-01126-4

Ejemplares similares

Unleashing the power of NK cells in anticancer immunotherapy
por: Vogler, Meike, et al.
Publicado: (2021)

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
por: Wu, Jingjing, et al.
Publicado: (2015)

Human NK cells, their receptors and function [Image: see text]
por: Quatrini, Linda, et al.
Publicado: (2021)

NK cell dysfunction in patients with COVID-19
por: Bi, Jiacheng
Publicado: (2022)

NK cell dysfunction in severe COVID-19: TGF-β-induced downregulation of integrin beta-2 restricts NK cell cytotoxicity
por: Barros-Martins, Joana, et al.
Publicado: (2022)

Transcriptomic perspectives of memory-like NK cells and aging
por: Wang, Dandan, et al.
Publicado: (2022)

Extended pluripotent stem cells facilitate mouse model generation
por: Xiang, Guanghai, et al.
Publicado: (2018)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer
por: Carlsten, Mattias, et al.
Publicado: (2023)

Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids
por: Särchen, Vinzenz, et al.
Publicado: (2023)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
por: Tognarelli, Sara, et al.
Publicado: (2018)

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma
por: Bexte, Tobias, et al.
Publicado: (2022)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Highlight: The Mystery of Mitochondrial Genomes
por: Venton, Danielle
Publicado: (2013)

A good gut feeling on Sarm1-mediated axon degeneration
por: von Saucken, Victoria E., et al.
Publicado: (2021)

Methionine restriction sensitizes cancer cells to immunotherapy
por: Lu, Weiqin, et al.
Publicado: (2023)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Selection and expansion of natural killer cells for NK cell-based immunotherapy
por: Becker, Petra S. A., et al.
Publicado: (2016)

Small molecule induced polymerization of BCL6 facilitates SIAH1 mediated degradation
por: Rana, Sandeep, et al.
Publicado: (2021)

Highlight: Mitochondrial First Steps Found in Jakobid Protists
por: Venton, Danielle
Publicado: (2013)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

Transcriptional suppression of CD8(+) T cell exhaustion for improving T cell immunotherapy
por: Yang, Xue, et al.
Publicado: (2021)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy
por: Särchen, Vinzenz, et al.
Publicado: (2022)

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army
por: Suleman, Sufyan, et al.
Publicado: (2017)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Immunotherapy with NK cells: recent developments in gene modification open up new avenues
por: Reindl, Lisa Marie, et al.
Publicado: (2020)

Fumarate hydratase inhibition activates innate immunity via mitochondrial nucleic acid release
por: Li, Xiang, et al.
Publicado: (2023)

CD5: from antiquated T cell marker to immunotherapy’s new hope
por: Schwarz, Sandra, et al.
Publicado: (2023)

Maybe she's NOT the boss: male–female crosstalk during sexual plant reproduction
por: Vogler, Hannes, et al.
Publicado: (2016)

Apaf-1/caspase-4 pyroptosome: a mediator of mitochondrial permeability transition-triggered pyroptosis
por: Shao, Gang, et al.
Publicado: (2021)

T-bet is essential for Th1-mediated, but not Th17-mediated, CNS autoimmune disease
por: O'Connor, Richard A, et al.
Publicado: (2013)

Cytotoxic FCER1G(+) innate-like T cells: new potential for tumour immunotherapy
por: Morrish, Emma, et al.
Publicado: (2022)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9bbe5uc6omupt49v0qo2ibihdh